Vimarsana
Biggest News Aggregation in the World

Page 3 - Noah Berkowitz News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Noah Berkowitz. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Noah Berkowitz Today - Breaking & Trending Today

Bristol Myers Squibb Receives European Commission Approval of Reblozyl (luspatercept) for Anemia in Adult Patients with Non-Transfusion-Dependent Beta Thalassemia - Vimarsana News

Bristol Myers Squibb Receives European Commission Approval of Reblozyl (luspatercept) for Anemia in Adult Patients with Non-Transfusion-Dependent Beta Thalassemia

Third authorized indication in Europe for Reblozyl, a first-in-class treatment for patients with diseases impacted by anemia Bristol Myers Squibb (NYSE: BMY) today announced that the European Commission

New therapy for anaemic myelodysplastic cancer patients - Vimarsana News

New therapy for anaemic myelodysplastic cancer patients

Reblozyl, the first erythroid maturation agent showed increased haemoglobin in transfusion-dependant patients with myelodysplastic syndromes.

Bristol Myers Squibb Withdraws Luspatercept sBLA for NTD Beta Thalassemia - Vimarsana News

Bristol Myers Squibb Withdraws Luspatercept sBLA for NTD Beta Thalassemia

Bristol Myers Squibb announced the withdrawal of the sBLA for luspatercept-aamt for the treatment of anemia in adults with NTD beta thalassemia.

Source: empr.com
Bristol Myers Squibb Withdraws Supplemental Biologics License Application (sBLA) for Reblozyl® (lusp - Vimarsana News

Bristol Myers Squibb Withdraws Supplemental Biologics License Application (sBLA) for Reblozyl® (lusp

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced that the company has withdrawn a supplemental biologics license application (sBLA) for Reblozyl® (luspatercept-aamt) for the treatment of anemia in adults with non-transfusion dependent (NTD) beta thalassemia. The Company could not ap...

Bristol Myers Squibb and Acceleron Present First Results from Phase 2 BEYOND Study of Reblozyl® in Adults with Non-Transfusion Dependent Beta Thalassemia - Vimarsana News

Bristol Myers Squibb and Acceleron Present First Results from Phase 2 BEYOND Study of Reblozyl® in Adults with Non-Transfusion Dependent Beta Thalassemia

Reblozyl was generally well tolerated and improvements in hemoglobin correlated with improved patient-reported outcomes over a continuous 12-week interval In the study, 89.6% of patients treated with Reblozyl remained transfusion free vs. 67.3% of patients in the placebo arm at weeks 1-24 Results featured in Presidential Symposium of European Hematology Association’s Virtual Congress as one of top six abstracts submitted Bristol Myers Squibb (NYSE: BMY) and Acceleron Pharma Inc. (NASDAQ: XLRN) today announced the first data from the Phase 2 BEYOND study evaluating Reblozyl ...